Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Cut to Strong Sell at Jefferies Financial Group

Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a moderate sell rating to a strong sell rating in a research note released on Tuesday,Zacks.com reports.

FMS has been the topic of several other reports. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Erste Group Bank downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Weiss Ratings cut Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 5th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. Finally, Truist Financial set a $28.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Monday, January 5th. Five investment analysts have rated the stock with a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Up 3.4%

NYSE:FMS opened at $23.43 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.00 and a current ratio of 1.26. The firm has a market cap of $13.58 billion, a P/E ratio of 12.27, a P/E/G ratio of 0.71 and a beta of 0.90. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.94 and a fifty-two week high of $30.46. The firm has a 50-day simple moving average of $23.30 and a two-hundred day simple moving average of $24.45.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its earnings results on Tuesday, February 24th. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.16. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $4.80 billion. Analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of large investors have recently made changes to their positions in FMS. Brooklyn Investment Group increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 5.4% during the 4th quarter. Brooklyn Investment Group now owns 8,860 shares of the company’s stock valued at $212,000 after purchasing an additional 450 shares during the last quarter. GAMMA Investing LLC grew its position in Fresenius Medical Care AG & Co. KGaA by 5.9% during the third quarter. GAMMA Investing LLC now owns 10,437 shares of the company’s stock valued at $275,000 after buying an additional 585 shares during the period. Hantz Financial Services Inc. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 10.5% during the fourth quarter. Hantz Financial Services Inc. now owns 7,370 shares of the company’s stock valued at $176,000 after buying an additional 699 shares during the last quarter. Fifth Third Bancorp increased its holdings in Fresenius Medical Care AG & Co. KGaA by 4.0% during the fourth quarter. Fifth Third Bancorp now owns 18,766 shares of the company’s stock valued at $447,000 after buying an additional 726 shares during the last quarter. Finally, Arax Advisory Partners raised its position in Fresenius Medical Care AG & Co. KGaA by 121.6% in the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after acquiring an additional 885 shares during the period. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.